mental health conditions, such as depression, anxiety, and attention deficit hyperactivity disorder.chronic medical conditions, such as diabetes, Parkinson’s disease, hyperthyroidism, and obstructive and central sleep apnea.It’s chronic insomnia that occurs with another condition.Ĭommon causes of chronic insomnia include: Secondary insomnia, also called comorbid insomnia, is more common. Primary chronic insomnia, which is also called idiopathic insomnia, doesn’t have an obvious cause or underlying medical condition. Insomnia is considered chronic if you have trouble sleeping at least three days per week for at least one month.Ĭhronic insomnia can be primary or secondary. physical discomfort, such as pain or being unable to assume a comfortable position.sleeping in an unfamiliar bed or surroundings, such as a hotel or new home.environmental factors that disrupt your sleep, such as noise or light.It’s the most common type of insomnia.Īcute insomnia is also referred to as adjustment insomnia because it typically occurs when you experience a stressful event, such as the death of a loved one or starting a new job.Īlong with stress, acute insomnia can also be caused by: Acute insomniaĪcute insomnia is short-term insomnia that can last from a few days to a few weeks. Each type is characterized by how long it lasts, how it affects your sleep, and the underlying cause. (2) Our data suggest that pregabalin as an add-on treatment is a reasonable choice for patients with focal epilepsy who have concomitant symptoms of an anxiety disorder.There are a few different types of insomnia. The add-on therapy resulted in the improvement of the depressive and anxiety symptoms, and insomnia, greater in those that experienced seizure resolution or reduction in their frequency.ĬONCLUSIONS: (1) Patients with focal epilepsy with concomitant anxiety disorder experience reduction in seizure frequency, improvement of anxiety, depressive symptoms and insomnia using PGB as an add-on therapy. At the beginning of the study, despite pregabalin administration, 60.7% of patients were above the diagnostic threshold for GAD diagnosis. After nine months, based on the intention-to-treat analysis, 27.1% (N = 253) of the subjects experienced seizure resolution, and 57.8% (N = 539) reduction in seizure frequency by at least 50%. During the study period (nine months) the mean dose was increased to 327 ± 163 mg. RESULTS: On the initial visit, the mean daily dose of pregabalin was 159 ± 82 mg. The number of epileptic seizures was monitored before and after the increase of the pregabalin dose. The severity of anxiety was assessed with GAD-7 Scale. PATIENTS AND METHODS: This open study involved 993 patients (46 ± 14 years old) suffering from epilepsy with focal seizures and concomitant GAD treated with pregabalin add-on therapy.
The aim of the study was to evaluate the effects of increasing the dose of previously taken pregabalin in a group of patients with focal epilepsy and generalized anxiety disorder (GAD). In clinical practice, drugs are often used at doses that are too low, which results in suboptimal levels of clinical improvement.
OBJECTIVE: The effectiveness of the treatment depends on the adequate dosage of medications.
0 kommentar(er)
